An antibody-drug conjugate designed through clone and isotype selection restricts the growth of CSPG4-expressing triple-negative breast cancer.

NPJ Precis Oncol · 2026 · PMC13096323 · PMID 41794948

Europe PMC DOI

hedged sentence

0.0560

closest p · 1.1× alpha

0.0560

boldest claim

The sentences

showed a trendp = 0.056so close (0.05 < p ≤ 0.1)

Similarly, transcriptomic data from chemotherapy-treated breast cancer patients showed a trend towards worse survival in CSPG4-high tumours (HR = 2.71, p = 0.056), supporting its association with pro-tumorigenic functions (Fig. 1D , Right Panel).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.